目次

Table of Content

1. Introduction to ATR Inhibition
1.1 Overview of ATR Protein and ATR Inhibition
1.2 History and Evolution of ATR Inhibitors

2. ATR Inhibitors: Research and Clinical Trials Overview by Indication
2.1 Solid Cancers
2.2 Hematological Cancers

3. Global ATR Inhibitors Market Outlook
3.1 Current Market Trends and Developments
3.2 Future Growth Avenues

4. ATR Inhibitors Development Trends by Region
4.1 US
4.2 EU
4.3 UK
4.4 Canada
4.5 China
4.6 Japan
4.7 Australia

5. Global ATR Protein Inhibitors Clinical Trials Overview
5.1 By Country
5.2 Indication
5.3 Phase
5.4 Therapy Class

6. Global ATR Protein Inhibitors Clinical Pipeline By Company, Indication and Phase
6.1 Research
6.2 Preclinical
6.3 Phase-I
6.4 Phase-I/II
6.5 Phase-II
6.6 Phase-III

7. Global ATR Inhibitors Market Drivers and Challenges
7.1 Drivers and Opportunities
7.2 Challenges and Restraints

8. Competitive Landscape
8.1 Antengene Corporation
8.2 Aprea
8.3 AstraZeneca
8.4 Bayer
8.5 Beijing Tide Pharmaceutical
8.6 Biocity Biopharmaceutics
8.7 Chipscreen Biosciences
8.8 IMPACT Therapeutics
8.9 Laevoroc Neuro-Oncology
8.10 Repare Therapeutics
8.11 Shanghai De Novo Pharmatech
8.12 Shanghai Junshi Biosciences
8.13 ShangPharma
8.14 Vertex Pharmaceuticals

List of Figures & Table
Figure 1-1: ATR Mediated DNA Damage Repair Signaling
Figure 1-2: Benefits of ATR Inhibitors
Figure 1-3: ATR inhibitors in Clinical Trials
Figure 1-4: ATR Inhibitors - History and Evolution

Figure 2-1: LATIFY Phase III Study - Initiation and Completion Years
Figure 2-2: ATRiBRAVE Phase II Study - Initiation and Completion Years
Figure 2-3: DASH Phase II Study - Initiation and Completion Years
Figure 2-4: MATRiX Phase II Study - Initiation and Completion Years
Figure 2-5: NCI-2021-10751 Phase I/II Study - Initiation and Completion Years
Figure 2-6: ACE-CL-110 Phase I Study - Initiation and Completion Years

Figure 3-1: ATR inhibitors - Future Growth Avenues

Figure 5-1: Global - ATR Protein Inhibitors Clinical Trials by Country (Numbers), 2023 and 2024
Figure 5-2: Global - ATR Protein Inhibitors Clinical Trials by Indication (Numbers), 2023 and 2024
Figure 5-3: Global - ATR Protein Inhibitors Clinical Trials by Phase (Numbers), 2023 and 2024
Figure 5-4: Global - ATR Protein Inhibitors Clinical Trials by Therapy Class (Numbers), 2023 and 2024

Figure 7-1: ATR Inhibitors Market Drivers
Figure 7-2: ATR Inhibitors Market Challenges

List of Tables
Table 4-1: US - National Cancer Institute Sponsored Clinical Trials for ATR Inhibitors
Table 4-2: EU - Ongoing Clinical Trials for ATR Inhibitors
Table 4-3: UK - Ongoing Clinical Trials for ATR Inhibitors
Table 4-4: Canada - Ongoing Clinical Trials for ATR Inhibitors
Table 4-5: China - Ongoing Clinical Trials for ATR Inhibitors
Table 4-6: Japan - Ongoing Clinical Trials for ATR Inhibitor M1774
Table 4-7: Australia - Ongoing Clinical Trials for ATR Inhibitors